Instalab

Escherichia Coli Test Stool

Get an early read on a gut bacterium linked to bowel inflammation and colorectal cancer risk.

Should you take a Escherichia Coli test?

This test is most useful if any of these apply to you.

Living With Gut Symptoms
If you have ongoing bloating, cramping, or changes in stool, this test can show whether an E. coli imbalance is part of the picture.
Family History of Colon Cancer
If colon cancer runs in your family, this test can flag a bacterial pattern researchers have linked to higher tumor risk in diet-exposed people.
On Long-Term PPIs or NSAIDs
If you have been on reflux or pain medications for years, this test shows whether they are shifting your gut balance in a pro-inflammatory direction.
Healthy but Optimizing Gut Health
If you are working on your microbiome, this test gives a baseline so you can measure whether your dietary changes are shifting things.

About Escherichia Coli

Billions of E. coli (Escherichia coli) bacteria are living inside your large intestine right now. Most are harmless lodgers, but certain strains and certain amounts can push your gut toward inflammation, tissue damage, and changes linked to inflammatory bowel disease and colorectal cancer.

This test looks at how much E. coli is growing in your stool, which reflects what is happening in the bacterial community lining your intestine. It is a research-grade window into gut balance, not a test for an active infection in your bladder or bloodstream.

What This Test Actually Measures

The test quantifies E. coli in your stool as part of a broader look at your gut microbiome (the trillions of bacteria living in your intestine). It is different from the E. coli test your doctor might order when you have burning urination or a fever. That test looks for E. coli growing in urine or blood, where its presence signals infection. A stool measurement instead reflects ecology: how much space E. coli is taking up relative to other bacteria in a place where some E. coli is normal.

E. coli is a Gram-negative bacterium, meaning it has a specific type of outer cell wall that shapes how your immune system reacts to it. Most strains are harmless gut residents. A smaller number, including adherent-invasive E. coli (AIEC) and strains carrying a DNA-damaging genetic element called the pks island, are linked to inflammation and cancer risk when they become too abundant.

Inflammatory Bowel Disease

Overgrowth of E. coli and related bacteria in the Enterobacteriaceae family is one of the most consistent microbial signatures of inflammatory bowel disease. A metagenomic analysis of 448 samples from people with Crohn's disease and ulcerative colitis found that the gut microbiome in both conditions was significantly shifted toward Enterobacteriaceae, with Escherichia as the main driver.

A specific subtype called adherent-invasive E. coli is found much more often in people with IBD than in people without it. A meta-analysis pooling multiple studies showed significantly higher prevalence of this strain in both Crohn's disease and ulcerative colitis patients compared to non-IBD controls, suggesting it may play a role in both diseases rather than being a passive bystander. In one cohort, people with ulcerative colitis who were colonized with multidrug-resistant E. coli had more severe disease than those who were not.

Colorectal Cancer Associations

A subset of E. coli strains carry a genetic toolkit called the pks island that produces a molecule capable of damaging DNA in the cells lining your colon. In two large US cohorts covering 134,775 people, a Western-style eating pattern was linked to about 3.5 times the risk of developing colorectal tumors that contained abundant pks-positive E. coli (hazard ratio 3.45, 95% CI 1.53 to 7.78) compared to tumors without the bacteria. The diet-cancer connection was strongest specifically for tumors with high pks E. coli, not for tumors without it.

A Japanese analysis of 968 people found no overall association between stool pks-positive E. coli and precancerous colon growths in that population, with adjusted odds ratio of 1.04 (95% CI 0.77 to 1.41). What this suggests is that E. coli levels alone are not a stand-alone cancer predictor. The risk appears to emerge when the wrong strain meets the wrong diet in the wrong person.

Reconciling These Findings

You may notice a tension in the research. Some studies show strong links between E. coli and disease, while others find nothing. This is not really a contradiction. E. coli is not a simple up-or-down marker like LDL cholesterol. It is a category that includes many different strains with very different biological effects. A moderate amount of harmless commensal E. coli looks identical to the same amount of pathogenic AIEC or pks-positive E. coli on a basic stool test. Interpreting your result means considering the total picture, including inflammation markers, symptoms, diet, and other microbiome findings, rather than treating the number as a verdict on its own.

Other Associations Worth Knowing

A study of 203 children found that an imbalance in gut chemicals produced by bacteria, linked to overrepresented Escherichia in stool, appeared as a metabolic signature of mild autism spectrum disorder. Separately, twin studies of people with ileal Crohn's disease show specific imbalances in gut bacteria involving E. coli that may help distinguish disease subtypes. These findings are still exploratory, but they suggest that E. coli abundance is connected to immune and neurological patterns beyond classic gut disease.

Reference Ranges

There is no universally agreed-upon clinical cutpoint for stool E. coli. Labs use different sequencing methods, different reference populations, and different reporting formats, which means the number you receive is best understood in comparison to your lab's own published reference range and to your own previous results. Most labs report E. coli abundance as either an absolute count or a relative percentage, flagging results that fall outside the middle of a healthy reference population.

CategoryWhat It Suggests
Within reference rangeE. coli abundance is in line with healthy controls used by the lab
Above reference rangeOvergrowth pattern associated in research with IBD-type inflammation and diet-driven cancer risk
Below reference rangeLow commensal abundance, sometimes seen after antibiotics or in disrupted microbiomes

Compare your results within the same lab over time. A result that moved from the middle of the range to the high end tells you something. A result that is slightly outside one lab's range but within another's does not.

When Results Can Be Misleading

  • Recent antibiotics: a course of antibiotics in the past several weeks can dramatically lower or raise E. coli depending on the drug class. Broad-spectrum antibiotics often allow E. coli and related bacteria to overgrow after suppressing competitors, and the normal community may take weeks to months to recover.
  • Acute diarrhea or travel: an active gut infection temporarily shifts microbiome composition. A stool test taken during or right after an episode of diarrhea will not reflect your usual state.
  • Recent colonoscopy prep: the bowel-cleansing solution used before a colonoscopy wipes out a large portion of your gut bacteria temporarily, which can distort results for weeks.
  • Sample collection errors: stool tests require a sample from the right part of the stool, stored correctly. Samples left at room temperature too long or contaminated during collection can produce misleading numbers.

Tracking Your Trend

A single stool E. coli reading is a snapshot of one moment in a living, changing community. Day-to-day variation can be substantial. What matters more is the trajectory. If your number is rising over repeated tests, or if it is persistently elevated across multiple samples taken months apart, that signals a real pattern. If it bounces around without a clear direction, that is normal biological noise.

A reasonable cadence is to get a baseline, retest in three to six months if you are making diet or supplement changes, and then at least annually to track your trend. If you are using this test to monitor an intervention for IBD, gut symptoms, or post-antibiotic recovery, retest in eight to twelve weeks to see whether the shift is holding.

What to Do With an Abnormal Result

A high E. coli result on its own does not diagnose anything. Pair it with markers of gut inflammation (calprotectin, secretory IgA), markers of beneficial bacteria (Faecalibacterium prausnitzii, Akkermansia muciniphila), and markers of digestion (pancreatic elastase). If E. coli is high and inflammation markers are also elevated, that combination warrants a conversation with a gastroenterologist, especially if you have symptoms like abdominal pain, bloody stools, or unintended weight loss.

If E. coli is high without inflammation, and you have no symptoms, the most productive next step is usually a dietary intervention aimed at shifting the broader community. Retest in three to six months to see whether the shift held.

What Moves This Biomarker

Evidence-backed interventions that affect your Escherichia Coli level

Increase
Eat a Western-style diet high in processed meat, refined grains, and sugar
A Western eating pattern is consistently linked to higher abundance of pro-inflammatory Enterobacteriaceae like E. coli in the gut. In two US prospective cohorts covering 134,775 people, the highest Western-diet tertile had about 3.5 times the risk of developing colorectal tumors rich in pks-positive E. coli (hazard ratio 3.45, 95% CI 1.53 to 7.78) compared to the lowest tertile, while associations were weaker or absent for tumors without these bacteria. The diet appears to create conditions where the more harmful E. coli strains thrive.
DietStrong Evidence
Up & Down
Take broad-spectrum antibiotics (amoxicillin-clavulanate, fluoroquinolones)
Broad-spectrum antibiotics initially wipe out a large portion of the gut bacterial community, then frequently allow E. coli and related bacteria to rebound and overgrow after competitors are suppressed. A systematic review found that amoxicillin-clavulanate increased E. coli counts while reducing beneficial anaerobes, with communities typically normalizing within about 35 days. If you are testing E. coli after recent antibiotic exposure, the number may not reflect your usual state.
MedicationStrong Evidence
Decrease
Follow a Mediterranean-style diet with high fiber, vegetables, and olive oil
A Mediterranean eating pattern and specific dietary fibers are associated with lower gut inflammation in people with inflammatory bowel disease, and they shift the microbial balance away from overgrown E. coli toward beneficial fiber-fermenting bacteria. A systematic review of diet and E. coli in IBD concluded that the Mediterranean diet appears protective against inflammation, while Western patterns promote it.
DietModerate Evidence
Increase
Take proton pump inhibitors (PPIs) long-term for reflux
PPIs reduce stomach acid, which normally kills bacteria swallowed with food. Their long-term use is linked to increased abundance of Gammaproteobacteria including Escherichia and other Enterobacteriaceae in the gut. A systematic review of non-antibiotic prescription drugs found PPIs significantly altered the intestinal microbiome, decreasing Clostridiales and increasing potentially pathogenic taxa including E. coli-like organisms. If you are on long-term PPI therapy, this drug-induced shift may be driving part of your elevated result, and it is worth discussing with your doctor whether continued use is necessary.
MedicationModerate Evidence
Increase
Take metformin for diabetes or prediabetes
Metformin causes a measurable shift in the gut microbiome, including increases in Escherichia and related Gammaproteobacteria. This is considered part of how metformin works, and some of its metabolic benefits may come through this microbiome change rather than in spite of it. The net clinical effect is generally beneficial for blood sugar control, so the microbiome shift should be interpreted in context if you are on metformin.
MedicationModerate Evidence
Increase
Use NSAIDs (ibuprofen, naproxen, aspirin) regularly
Regular NSAID use is associated with increased gut Enterobacteriaceae (the family including E. coli) and with gut barrier damage. A study of 155 adults found that the type of NSAID used significantly shaped the microbiome, with distinct bacterial populations associated with each drug type. NSAID-driven injury to the gut lining is partly mediated by lipopolysaccharide from Enterobacteriaceae, creating a feedback loop where higher E. coli worsens the damage NSAIDs cause.
MedicationModerate Evidence
Increase
Use opioid pain medications long-term
Chronic opioid use is linked to gut dysbiosis with increased pathogenic taxa, including E. coli-like organisms. The slowing of gut motility caused by opioids creates conditions that favor bacterial overgrowth. This change contributes to opioid-induced constipation and may worsen broader gut inflammation patterns.
MedicationModerate Evidence
Increase
Take antipsychotic medications
Antipsychotic drugs have been shown to exacerbate gut dysbiosis, with increased pathogenic taxa including Enterobacteriaceae and altered Bacteroidetes to Firmicutes ratios. A systematic review found these drugs led to decreased diversity and increased susceptibility to infections. If you are on an antipsychotic, an elevated E. coli result may partly reflect the drug's microbiome effect rather than a problem you can easily address through diet alone.
MedicationModerate Evidence

Frequently Asked Questions

References

12 studies
  1. Nadalian B, Yadegar a, Houri H, Olfatifar M, Shahrokh S, Asadzadeh Aghdaei H, Suzuki H, Zali MJournal of Gastroenterology and Hepatology2020
  2. Yadav a, Shinde P, Mohan H, Dhar MS, Ponnusamy K, Marwal R, Vs R, Goyal S, Kedia S, Ahuja V, Sharma KKInternational Journal of Antimicrobial Agents2024
  3. Arima K, Zhong R, Ugai T, Zhao M, Haruki K, Akimoto N, Lau M, Okadome K, Mehta RS, Väyrynen J, Ogino SGastroenterology2022
  4. Iwasaki M, Kanehara R, Yamaji T, Katagiri R, Mutoh M, Tsunematsu Y, Sato M, Watanabe K, Hosomi K, Kakugawa Y, Ikematsu H, Hotta K, Kunisawa J, Wakabayashi K, Matsuda TCancer Science2021